Compare NEN & CNXU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
| Metric | NEN | CNXU |
|---|---|---|
| Founded | 1977 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 215.9M |
| IPO Year | 1995 | 2025 |
| Metric | NEN | CNXU |
|---|---|---|
| Price | $52.00 | $3.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 922.0 | ★ 189.0K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,196,544.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | ★ 10.76 | N/A |
| 52 Week Low | $50.51 | $3.86 |
| 52 Week High | $73.50 | $13.66 |
| Indicator | NEN | CNXU |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 33.44 |
| Support Level | N/A | N/A |
| Resistance Level | $57.00 | $5.47 |
| Average True Range (ATR) | 1.25 | 0.46 |
| MACD | -0.23 | 0.05 |
| Stochastic Oscillator | 22.96 | 14.25 |
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.